INTRODUCTION AND OBJECTIVES: A conus medullaris syndrome results from an Injury to the conus medullaris and cauda equine portions of the spinal cord. The clinical presentation is characterized by a lower motor neuron weakness affecting both skeletal muscles and pelvic organs with signs of paralysis, sensory disturbance and impairments of bladder, bowel, and sexual functions. The goal of the present study was to translate the unilateral lumbosacral ventral root avulsion (VRA) injury model from the rat to rhesus macaques, and to determine early and late effects of pelvic target denervation on lower urinary tract and external anal sphincter (EAS) function.
INTRODUCTION AND OBJECTIVES: A conus medullaris syndrome results from an Injury to the conus medullaris and cauda equine portions of the spinal cord. The clinical presentation is characterized by a lower motor neuron weakness affecting both skeletal muscles and pelvic organs with signs of paralysis, sensory disturbance and impairments of bladder, bowel, and sexual functions. The goal of the present study was to translate the unilateral lumbosacral ventral root avulsion (VRA) injury model from the rat to rhesus macaques, and to determine early and late effects of pelvic target denervation on lower urinary tract and external anal sphincter (EAS) function.
METHODS: A total of 6 female rhesus macaques were included. A unilateral L6-S3 VRA injury was performed and resulted in a lesion of all preganglionic parasympathetic fibers of the ipsilateral pelvic nerve and all somatic motor fibers of the ipsilateral pudendal nerve. Urodynamic studies and EAS electromyography (EMG) were performed under ketamine anesthesia in control subjects (n¼6), and at 1 month and 6 months after the unilateral VRA injury (n¼4).
RESULTS: The bladder infusion rate was between 85 and 120 mL/min to partially fill the bladder and induce reflex voiding. Poor voiding efficiency and compliance, and a slower urine flow rate were found in VRA subjects. The EAS guarding reflex was tested using a rectal probe. The maximum amplitude and area under the curve of EAS EMG were significantly decreased at 1 month after injury, but recovered at 6 months. Power spectrum ( Fig. 1 ) showed that the peak frequency increased at 1 month after injury, but it was reduced to normal state at 6 month. The mean frequency was decreased at 1 and 6 months after injury. CONCLUSIONS: This model eliminated the parasympathetic fibers of pelvic nerve and the somatic motor fibers of pudendal nerve, which resulted in detrusor underactivity and poor EAS contractility. Power spectrum analysis indicated that fewer motor units fired during EAS contraction after injury. This model in rhesus macaques mimics the clinical phenotype of conus medullaris syndrome using a lumbosacral VRA injury approach in long-term studies. It may provide a useful model to test the utility of emerging treatments after denervation of pelvic targets. We recently characterized a murine model of coronavirus-induced encephalomyelitis (CIE model), and confirmed that CIE mice develop neurogenic bladder dysfunction that was comparable with neurogenic LUTS observed in MS patients. Identified mechanisms were morphological changes in the centers controlling micturition, spinal cord gliosis, and increased expression of pro-inflammatory cytokines. In the current study, we aimed to understand the long-term effects of neurodegenerative changes on micturition patterns and bladder physiology, as well as uncover the mechanisms of long-lasting neurogenic bladder dysfunction.
Source of
METHODS: Adult C57BL/6J mice were inoculated with 20 ml of mouse hepatitis virus (MHV, N¼44, CIE mice) or PBS (N¼19). Neurological symptoms and mouse weight were recorded daily, and voiding behavior weekly up to 8 wks pi. Neurologic symptoms were evaluated by the Clinical Symptoms Score (CSS) on a scale from 0 (asymptomatic) to 4 (quadriparesis/paralysis). Detrusor contractility was evaluated in vitro at 10 wks. Based on CSS, CIE mice were assigned to 2 groups: recovery (REC group), and relapse (RELAP group). RELAP group was defined based on: (1) presence of symptomfree period at least for 24 hrs after initial rise in CSS, (2) presence of 2 symptom-free periods (24 h duration each), and (3) CSS>2 during the relapse.
RESULTS: Long-term follow up of CIE mice revealed two different neurological phenotypes: 1-recovery from initial acute neurological impairment (REC, 73.5% of all CIE mice, N¼25); and 2-relapse in symptoms (RELAP, 26.5% of all CIE mice, N¼9). Eight percent of mice in REC group still had CSS!2 at 8 wks in comparison to 22.2% in RELAP group. Animals in both REC and RELAP groups showed the most significant weight loss at 1wk. (22.3AE0.28g at baseline vs 16.5AE0.3g in REC group, and 9.2AE0.86g in RELAP group, p<0.05). Isolated bladder strips from CIE mice did not have significant differences in muscarinic responses to EFS, however, RELAP group showed significantly decreased M3 responses along with increased micturition frequency at 5-6 wks. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1149 CONCLUSIONS: Long-term follow up of CIE mice revealed two differential phenotypes of neurologic impairment mimicking two forms of MS in humans: relapsing-remissive MS and chronic inflammatory type of MS. Mice in RELAP group had a decreased response to M3 agonists suggesting that anti-muscarinic drugs may have limited effects on neurogenic bladder in this type of MS.
Source of Funding: This work was supported by P20 DK097819 grant (to A.M.P.), and AUA Scholar Award (to S.L.).
MP85-06
BRAIN NETWORKS CONTROLLING BLADDER FILLING AND VOIDING Hanneke Verstegen*, John Mathai, Mark Zeidel, Boston, MA; Joel Geerling, Iowa City, IA INTRODUCTION AND OBJECTIVES: Lower urinary tract symptoms (LUTS) are common and poorly understood; treatment is often ineffective. Failure of neural control of bladder function likely contributes to LUTS symptoms in many patients. Prior studies have shown that the pontine micturition center (PMC) directly controls voiding. Within the PMC corticotropin releasing hormone neurons (PMC CRH ) project axons directly to spinal sacral cord nuclei that control bladder contraction. Here we show that PMC CRH neurons are critical for voiding, and identify neurons, particularly in the ventrolateral periaqueductal gray (PAG VL ) which directly modulate PMC CRH and alter voiding.
METHODS: We inject adeno-associated viruses expressing proteins in a Cre-dependent fashion into anatomically defined regions of mice expressing Cre recombinase in specific neural types, to cause highly selective expression of these probes in target neuron populations. We monitor conscious voiding with micturition video thermography (MVT), and CMG under anesthesia while monitoring/ stimulating specific neuron groups.
RESULTS: Stimulating PMC CRH neurons using designer receptors exclusively activated by designer drugs (DREADDs) produces urinary frequency in awake mice and on anesthetized CMG. Also, ablating PMC CRH neurons by selective expression of diphtheria toxin A disrupts normal voiding and the normal CMG voiding reflex. To identify neurons which provide input to PMC CRH , we used modified rabies virus and cholera toxin B labeling of PMC CRH and confirmed our results with viral anterograde tracing. Afferents to PMC CRH are located in PAG VL , the preoptic area, the lateral hypothalamic area, and other sites. Because sacral afferents sensing bladder filling project to PAG VL we determined the impact of stimulating Glutamatergic or GABA-ergic neurons (PAG VL -GLUT or PAG VL GABA ) in this region. Chemogenetic or optogenetic stimulation of PAG VL GLUT neurons leads to voiding and detrusor contraction. By contrast, chemogenetic or optogenetic activation of PAG VL GABA inhibits voiding and delays detrusor contraction on CMG.
CONCLUSIONS: 1. PMC CRH are driver neurons for detrusor contraction/voiding. 2. PAG VL GLUT project to PMC CRH , and when fired drive voiding/detrusor contraction. 3. PAG VL GABA project to PMC CRH and inhibit voiding/detrusor contraction. PAG VL , which receives bladderbased sacral afferents, likely controls bladder filling, and is a potential target in efforts to control urge incontinence and urgency symptoms of LUTS.
Source of Funding: P20 DK103086

MP85-07 FUNCTIONAL NEUROIMAGING OF URINE STORAGE AND VOIDING IN MICE
Bryce MacIver*, Aaron Grant, Timothy Pagliaro, David Alsop, John Mathai, Mark Zeidel, Boston, MA INTRODUCTION AND OBJECTIVES: Lower urinary tract symptoms (LUTS) are common and poorly understood; treatment is often ineffective. Failure of neural control of bladder function likely contributes to LUTS symptoms in many patients. Mice are continent and serve as excellent models of LUTS, in part because they can be manipulated genetically. To relate what is learned in mice to humans, we have developed functional MRI methods for mice which mirror those in humans. Such methods will allow us to compare directly the activation patterns of mouse and human brains during bladder filling and voiding, in normal and disease states.
METHODS: Mice are anesthetized with urethane and a catheter is implanted in the bladder dome. Blood Oxygen Level Detection Magnetic Resonance Imaging (BOLD-MRI) is carried out in a Bruker 9.4T magnet with a 4 element mouse brain phased array coil. A series of 2D multislice gradient echo-planar images are acquired every 2s, while the mouse undergoes cystometry. 25 slices are acquired with slices of 500mm, interslice distance 600mm and in-plane resolution of 250mm. Imaging occurs over a 45 minute time frame during which the mouse undergoes 10-15 voiding cycles (CMG). Data are analyzed with Statistical Parameter Mapping (SPM12) software using mouse brain adaptations. Linear modeling proceeds in 2 stages; first by providing a statistical map of the brain of individual animals and second by combining results across all animals in a group.
RESULTS: Preliminary results on female C57BL6/J (n ¼5) with a fixed effects analysis identified candidate regions across the brain with clear activation in the right Pontine Micturition Center (PMC) observed, which was confirmed by a region based random effects analysis. Negative contrast identified more extensive regions such as the periaqueductal gray and inferior colliculus with an indication that these regions are 00 switched off 00 during the transition to voiding.
CONCLUSIONS: Although technically challenging due to the small size, BOLD-MRI on mice is feasible and reveals regions of brain activation related to voiding cycles. Development of this technique along with fine mapping of brain circuits related to voiding will help define mechanisms of LUTS in mouse models that should be translatable to human disease. (dLPP>40) have been associated with deterioration of renal function in children. As such, dLPP>40, despite clean intermittent catheterization (CIC) and anticholinergics, often mandates augmentation or diversion. While we recommend augmentation cystoplasty or diversion to appropriate patients, many elect for non-surgical management. Non-surgical management consists of rigorous urodynamic (UDS) and renal ultrasound (RUS) follow-up, paired with adjustments to CIC routine to keep bladder volumes below that volume at which dLPP>40, adjustments to anticholinergics, and intradetrusor botulinum toxin Type A (BTX). We describe the renal function outcomes of nonsurgical management of adults with poorly compliant (dLPP>40) NGB.
Source of Funding
METHODS: We retrospectively reviewed the charts of all patients at our Gillette Lifetime adult congenital urology clinic undergoing UDS from January 2011 to June 2016. Patients with dLPP>40 who opted for non-surgical management were included; this study was noted as their 00 index UDS 00 for calculation of follow-up. The primary endpoint was deterioration of renal function as evidenced by change in chronic kidney disease (CKD) stage, progression to CKD-III, or new/worsening hydronephrosis.
RESULTS: Of 210 patients who underwent UDS, 45 had dLPP>40. After exclusions for incomplete data (n¼7) or augmentation cystoplasty (n¼11), 27 were the subject of study. 15/27 (56%) were women and all 27 were Caucasian. Median age was 29 years (IQR 25, e1150
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